Gainers Profound Medical (NASDAQ:PROF) shares moved upwards by 21.5% to $6.9 during Thursday's

Analysts initiate: Sell GEV ($470); Buy IFRX ($8), LYNX ($21); Overweight FRSH ($18); Outperform NPW

Needham analyst Joseph Stringer initiates coverage on InflaRx (NASDAQ:IFRX) with a Buy rating and

Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market se

Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and r

InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.10) per share which missed the analyst consen

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics b

Raymond James analyst Ryan Deschner upgrades InflaRx (NASDAQ:IFRX) from Outperform to Strong Buy

HC Wainwright & Co. analyst Matthew Keller maintains InflaRx (NASDAQ:IFRX) with a Buy and rai

Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and r

All ordinary shares in the offering are being sold by the Company. The offering is expected to close

InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of es

InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by

InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by

InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by

Guggenheim analyst Yatin Suneja maintains InflaRx (NASDAQ:IFRX) with a Buy and lowers the price t

InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.17) per share which beat the analyst consensu

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics b

InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by

Several biotech stocks are showing renewed strength over the past week, with their Momentum scores s

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarte

  On Wednesday, 215 companies set new 52-week lows.

  On Tuesday, 540 companies set new 52-week lows.

  On Friday, 1043 companies hit new 52-week lows.

  During Wednesday's trading, 435 companies set new 52-week lows.

  On Monday morning, 207 companies hit new 52-week lows.

  During the morning session on Thursday, 152 stocks hit new 52-week lows.

Gainers

    Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows.

    During the morning session on Thursday, 67 stocks hit new 52-week lows.

Gainers Pandion Therapeutics, Inc. (NASDAQ: PAND) shares surged 133.4% to close at $59.81 on Thu

Gainers Curis, Inc. (NASDAQ: CRIS) stock climbed 354.9% to close at $6.55 on Tuesday after the co

Gainers Extraction Oil & Gas, Inc. (NASDAQ: XOG) shares climbed 247.9% to close at $1.48 on M